Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise in ...

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...

AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...

– Late-breaking data from a head-to-head study evaluating SKYRIZI ® (risankizumab) versus STELARA ® (ustekinumab) in moderate to severe Crohn's disease will be presented – Analyses on clinical and ...

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with moderate to severe forms of ulcerative colitis, broadening the company’s arsenal ...

AbbVie has received good news from the European Medicines Agency for a new use of its anti-inflammation drug Skyrizi, one of the best-selling products in its portfolio, now that blockbuster drug ...

OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ...